These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Effect of PI3K/AKT pathway on cisplatin resistance in non-small cell lung cancer].
    Author: Zhang Y, Lu H, Xu G.
    Journal: Zhongguo Fei Ai Za Zhi; 2014 Aug 20; 17(8):635-42. PubMed ID: 25130971.
    Abstract:
    Accumulating evidences indicate that aberrant activation of PI3K/AKT pathway in non-small cell lung cancer plays a vital role in tumor cell proliferation,apoptosis, and survival including drug resistance. Cisplatin as first-line chemotherapy are in widespread clinical use in patients with non-small cell lung cancer, however, the development of cisplatin resistance significantly impedes its clinic efficacy. Cisplatin resistance is a complicated process that various mechanisms participating in to interact, of which PI3K/AKT pathway keeping sustained activated is one of the most important reasons. This article reviewed the progress of research on the relationship between PI3K/AKT pathway and cisplatin resistance. 研究表明，PI3K/AKT信号通路在非小细胞肺癌存在异常激活，对肿瘤细胞的增殖、凋亡、存活、耐药等起着重要的作用。顺铂是临床最常用一线化疗药物，但随着治疗的进展肿瘤对其耐药的现象越来越普遍，严重制约其临床效果。顺铂耐药是多种机制共同参与的复杂过程，其中PI3K/AKT通路或其组分持续被激活是非常重要的因素之一。本文对二者关系研究领域的进展作一综述。
    [Abstract] [Full Text] [Related] [New Search]